Zhejiang Provincial Hospital Association Pharmaceutical Specialized Professional Committee, Zhejiang Hospital Pharmacy Administration Quality Control Center, Zhejiang Anticancer Association Tumor Clinical Pharmacy Professional Committee, Zhejiang Pharmaceutical Association Anti-tumor Drug Professional Committee. Practice Guidelines for the Off-label Use of Antibodies Targeting Lymphocyte[J]. Chinese Journal of Modern Applied Pharmacy, 2024, 41(20): 2868-2878. DOI: 10.13748/j.cnki.issn1007-7693.20240758
    Citation: Zhejiang Provincial Hospital Association Pharmaceutical Specialized Professional Committee, Zhejiang Hospital Pharmacy Administration Quality Control Center, Zhejiang Anticancer Association Tumor Clinical Pharmacy Professional Committee, Zhejiang Pharmaceutical Association Anti-tumor Drug Professional Committee. Practice Guidelines for the Off-label Use of Antibodies Targeting Lymphocyte[J]. Chinese Journal of Modern Applied Pharmacy, 2024, 41(20): 2868-2878. DOI: 10.13748/j.cnki.issn1007-7693.20240758
    • OBJECTIVE To provide a reference for the off-label use of antibodies targeting lymphocytes and to promote the rational clinical use of this type of drug.
      METHODS A multidisciplinary team of experts was established and the guidelines were developed through many rounds of expert discussion based on evidence-based medicine.
      RESULTS A total of 148 items on off-label use supported by sufficient evidence were included, including 4 items on CD3 and CD19 bispecific antibodies, 103 items on CD20 antibodies, 23 items on antibody-drug conjugate (ADC) targeting CD30, 17 items on CD38 antibodies and 1 item on ADC targeting CD79b.
      CONCLUSION This guideline clarifies the off-label use of antibodies targeting lymphocytes with sufficient evidence, and provides a practical reference for the off-label use of this type of drug.
    • loading

    Catalog

      Turn off MathJax
      Article Contents

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return